Value-Based Pricing for Drugs with Accelerated Approval Incorporating Uncertainty and Risk Aversion
Author(s)
Jiao B, Hsieh Y(, Verguet S
Harvard T.H. Chan School of Public Health, Boston, MA, USA
OBJECTIVES: The U.S. Food and Drug Administration accelerated approval (AA) program allows novel therapies to reach patients based on preliminary clinical evidence, in spite of potentially large uncertainties remaining with respect to their efficacy. Cost-effectiveness analyses (CEAs) could be conducted to inform the value-based price (VBP) of AA drugs, for which the incremental net monetary benefit (iNMB) compared with the standard of care (SoC) is set to zero. Such CEA approaches implicitly assume that the payers are risk neutral, even though they are likely risk averse. We propose a methodology to determine the VBP of AA drugs that explicitly incorporates risk aversion.
METHODS: We prescribe a payer’s utility by using a constant relative risk aversion (CRRA) utility function for the iNMB of an AA drug (relative to SoC); and this CRRA utility function is combined with the expected value of perfect information metric. The risk-averse VBP of the AA drug is then computed when the expected utility of the iNMB of an AA drug with perfect evidence (on drug efficacy) equals the iNMB of that drug with preliminary evidence. We illustrate our approach with the case study of a hypothetical AA drug for patients with relapsed or refractory multiple myeloma, using a range of input parameters for quantifying uncertainties and the CRRA coefficients.
RESULTS: We observe substantial changes when incorporating risk aversion into the VBP of AA drugs. As a case in point, in our hypothetical myeloma case study, the risk-neutral VBP of the AA drug would be $9,000 per month under a willingness to pay of $100,000 per quality-adjusted life year; while it could decrease to as low as $5,000 per month for a risk-averse payer.
CONCLUSIONS: Incorporating risk aversion and associated utility into value of information frameworks enables the explicit valuation of uncertainty into the determination of the VBP for risk-averse payers.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 6, S2 (June 2023)
Acceptance Code
P42
Topic
Economic Evaluation, Health Policy & Regulatory
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis, Pricing Policy & Schemes, Value of Information
Disease
Drugs, Oncology, rare-orphan-diseases